{"title":"[Ocular graft versus host disease].","authors":"Philipp Steven, Tina Dietrich-Ntoukas","doi":"10.1007/s00347-025-02212-y","DOIUrl":null,"url":null,"abstract":"<p><p>Ocular graft versus host disease (GVHD) following allogeneic hematopoietic stem cell transplantation (HSCT) is predominantly an inflammatory and destructive ocular surface disease with increasing incidence. It not only leads to a reduced quality-of-life but can also impair vision and in severe cases lead to blindness. The occurrence of GVHD can lead to a severe, often refractory disorders of the ocular surface, which is associated with chronic inflammation. The occurrence of corneal involvement is a major problem. The establishment of comprehensive care structures and individually adapted stage-appropriate treatment in interdisciplinary collaboration with colleagues in hemato-oncology is therefore of particular importance.</p>","PeriodicalId":72808,"journal":{"name":"Die Ophthalmologie","volume":" ","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2025-03-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Die Ophthalmologie","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1007/s00347-025-02212-y","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0
Abstract
Ocular graft versus host disease (GVHD) following allogeneic hematopoietic stem cell transplantation (HSCT) is predominantly an inflammatory and destructive ocular surface disease with increasing incidence. It not only leads to a reduced quality-of-life but can also impair vision and in severe cases lead to blindness. The occurrence of GVHD can lead to a severe, often refractory disorders of the ocular surface, which is associated with chronic inflammation. The occurrence of corneal involvement is a major problem. The establishment of comprehensive care structures and individually adapted stage-appropriate treatment in interdisciplinary collaboration with colleagues in hemato-oncology is therefore of particular importance.